| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.60▲ | 2.60▲ | 2.63▼ | 2.59▲ | 5.19▼ |
| MA10 | 2.61▼ | 2.66▼ | 2.64▼ | 4.74▼ | 6.25▼ |
| MA20 | 2.66▼ | 2.57▲ | 2.53▲ | 5.75▼ | 6.77▼ |
| MA50 | 2.54▲ | 3.13▼ | 4.51▼ | 6.52▼ | 7.10▼ |
| MA100 | 2.97▼ | 4.98▼ | 5.69▼ | 7.03▼ | 10.79▼ |
| MA200 | 4.91▼ | 6.36▼ | 6.67▼ | 7.13▼ | 95.15▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.014▼ | 0.065▲ | 0.157▲ | -0.489▼ | -0.443▼ |
| RSI | 47.774▼ | 40.556▼ | 27.978▼ | 23.074▼ | 32.819▼ |
| STOCH | 19.488▼ | 29.777 | 56.540 | 6.093▼ | 34.607 |
| WILL %R | -85.714▼ | -64.516 | -50.000 | -94.341▼ | -95.456▼ |
| CCI | -40.634 | -18.995 | 24.720 | -93.288 | -265.322▼ |
|
Tuesday, September 22, 2026 04:54 PM
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/09/26 | 2.68 | 2.7599 | 2.53 | 2.60 | 60,791 |
| 22/09/26 | 2.47 | 2.83 | 2.32 | 2.72 | 231,582 |
| 21/09/26 | 2.49 | 2.54 | 2.33 | 2.45 | 171,365 |
| 18/09/26 | 2.80 | 2.80 | 2.3001 | 2.49 | 527,170 |
| 17/09/26 | 3.23 | 3.35 | 2.70 | 2.71 | 1,420,924 |
| 16/09/26 | 6.83 | 7.15 | 6.52 | 6.68 | 28,626 |
| 15/09/26 | 6.89 | 7.10 | 6.65 | 6.86 | 42,663 |
| 14/09/26 | 7.195 | 7.60 | 6.92 | 6.92 | 61,771 |
| 11/09/26 | 6.79 | 7.3597 | 6.64 | 7.33 | 66,697 |
| 10/09/26 | 6.52 | 6.7999 | 6.50 | 6.64 | 59,504 |
|
|
||||
|
|
||||
|
|